2Prause JU, Manthorpe R, Oxholm P, et al. Definition and criteria for Sjogren's syndrome used by the contrib- utors to the First International Seminar on Sjogren's syndrome - 1986 [ J ]. Scand J Rheumatol Suppl, 1986, 61 : 17 - 18.
9Ukai Y,Taniguchi N, Takeshita K, et al. Chronic ane- thole trithione treatment enhances the salivary secre- tion and increases the muscarinic acetylcholine recep- tors in the rat submaxillary gland [ J ]. Arch Int Phar- macodyn Ther, 1984,271 (2) :206 - 212.
5B.u.cheler M,Wirz C,Sch.u.tz A,et al.Tissue engi-neering of human salivary gland organoids[J].Acta O-tolaryngol,2002,122(5):541-545.
6Johnson JT,Ferretti GA,Nethery WJ,et al.Oral pi-locarpin for post-irradiation xerostomia in patients withhead and neck cancer[J].N Engl J Med,1993,329(6):390-395.
7Nishioka T,Shirato H,Arimoto T,et al.Reduction ofradiation-induced xerostomia in nasopharyngeal carci-noma using CT simulation with laser patient marking andthree-field irradiation technique[J].Int J Radiat OncolBio Phys,1997,38(4):705-712.
8Rode M,Smid L,Budihna M,et al.The influence ofpilocarpine and biperiden on pHvalue and calcium,phos-phate,and bicarbonate concentrations in saliva duringand after radiotherapy for head and neck cancer[J].Oralsurg Oral Med Oral Pathol,2001,92(5):509-514.
9Anderson MW,Izutsu KT,Rice JC.Parotid glandpathophysiology after mixed gamma and neutron irra-diation of cancer patients[J].Oral surg Oral Med OralPathol,1981,52(3):495-500.
10Wiseman LR, Faulds D. Oral pilocarpine. Areview of its pharmacological properties and clinical potential in xerostomia[J]. Drugs, 1995, 1:143 - 155.
